Heterogeneity of neoplastic stem cells: Theoretical, functional, and clinical implications

Cancer Research

Volumn 73, Issue 3, 2013, Pages 1037-1045

  Valent, Peter ^a   Bonnet, Dominique ^c   Wöhrer, Stefan ^b   Andreeff, Michael ^d   Copland, Mhairi ^e   Chomienne, Christine ^f,g,h   Eaves, Connie ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Bone Marrow Transplantation Unit   (Austria)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f SAINT LOUIS HOSPITAL   (France)

^g INSERM   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CANCER STEM CELL; CELL CLONE; CELL FUNCTION; CELL HETEROGENEITY; CELL POPULATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; CLINICAL RESEARCH; EARLY CANCER; EPIGENETICS; GENE MUTATION; GENE SEQUENCE; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROGENY; REVIEW; THEORETICAL STUDY;

DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PRECANCEROUS CONDITIONS;

EID: 84873474915     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3678     Document Type: Review

References (75)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Calabrese P, Tavare S, Shibata D. Pretumor progression: clonal evolution of human stem cell populations. Am J Pathol 2004;164: 1337-46.
3. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53.
4. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9: M57-60.
5. Illingworth CJ, Mustonen V. Distinguishing driver and passenger mutations in an evolutionary history categorized by interference. Genetics 2011;189:989-1000.
6. MaQC, Ennis CA, Aparicio S. Opening Pandora's Box-the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. Curr Opin Genet Dev 2012;22:3-9.
7. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102: 4504-11.
8. Dessars B, De Raeve LE, Morandini R, Lefort A, El Housni H, Ghanem GE, et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol 2009;129:139-47.
9. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
10. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011;11: 726-34.
11. Valent P, Jager E, Mitterbauer-Hohendanner G, Mullauer L, Schwarzinger I, Sperr WR, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res 2011;1:531-41.
12. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481: 306-13.
13. Bowie MB, Kent DG, Dykstra B, McKnight KD, McCaffrey L, Hoodless PA, et al. Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties. Proc Natl Acad Sci U S A 2007;104:5878-82.
14. Knoblich JA. Mechanisms of asymmetric stem cell division. Cell 2008;132:583-97.
15. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012;12:133-43.
16. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120:2254-64.
17. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103: 2794-9.
18. Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol 2008;26:2911-5.
19. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
20. Wilson A, Laurenti E, Trumpp A. Balancing dormant and self-renewing hematopoietic stem cells. Curr Opin Genet Dev 2009;19:461-8.
21. Van Keymeulen A, Blanpain C. Tracing epithelial stem cells during development, homeostasis, and repair. J Cell Biol 2012;197:575-84.
22. Morshead CM, Craig CG, van der Kooy D. In vivo clonal analyses reveal the properties of endogenous neural stem cell proliferation in the adult mammalian forebrain. Development 1998;125:2251-61.
23. Ashkenazi R, Gentry SN, Jackson TL. Pathways to tumorigenesis-modeling mutation acquisition in stem cells and their progeny. Neoplasia 2008;10:1170-82.
24. Lopez-Corral L, Sarasquete ME, Bea S, Garcia-Sanz R, Mateos MV, Corchete LA, et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia 2012;26:2521-9.
25. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975- 2009-pops09/.
26. Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012;44:642-50.
27. Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets 2011;11:56-71.
28. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12:767-75.
29. Cazzaniga G, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I, et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood 2011;118:5559-64.
30. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866-71.
31. Forsberg AM, Kjellström L, Agreus L, Nixon A, Nyhlin H, Talley NJ, et al. Prevalence of colonic neoplasia and advanced lesions in the normal population: a prospective population-based colonoscopy study. Scand J Gastroenterol 2012;47:184-90.
32. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
33. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
34. Brosnan JA, Iacobuzio-Donahue CA. A new branch on the tree: nextgeneration sequencing in the study of cancer evolution. Semin Cell Dev Biol 2012;23:237-42.
35. Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma 1993;11 Suppl 1:245-53.
36. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003;17:1211-62.
37. Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC, et al. BCRABL-transformedGMPas myeloid leukemic stemcells. Proc Natl Acad Sci U S A 2008;105:17967-72.
38. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008;22:1841-8.
39. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006;108:3548-55.
40. Shih AH, Levine RL. Molecular biology of myelodysplastic syndromes. Semin Oncol 2011;38:613-20.
41. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
42. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-43.
43. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011;19:138-52.
44. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-9.
45. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010;7:403-17.
46. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15: 907-13.
47. Mimeault M, Johansson SL, Batra SK. Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies. PLoS ONE 2012;7:e31919.
48. Zheng W, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-e14.
49. Graf T, Enver T. Forcing cells to change lineages. Nature 2009; 462:587-94.
50. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011;469:362-7.
51. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011;208:653-61.
52. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012;22:457-72.
53. Brugieres L, Remenieras A, Pierron G, Varlet P, Forget S, Byrde V, et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 2012;30:2087-93.
54. Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA, et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet 2012; 44:277-84.
55. Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012;148:873-85.
56. Pierce GB, Wallace C. Differentiation of malignant to benign cells. Cancer Res 1971;31:127-34.
57. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012;10:678-84.
58. Graf T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 2011;9:504-16.
59. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-23.
60. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633-44.
61. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011;108:7950-5.
62. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012;148:1015-28.
63. Dazzi F, Hasserjian R, Gordon MY, Boecklin F, Cotter F, Corbo M, et al. Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J 2000;1:307-15.
64. Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005;19:435-41.
65. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010;24:1823-33.
66. Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004;103:4285-93.
67. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
68. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008; 270:1-9.
69. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11: 220-8.
70. Kobayashi CI, Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol 2012;227:421-30.
71. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012;119:4253-63.
72. Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012;6:620-36.
73. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-9.
74. Au WY, Lie AK, Ma SK, Wan TS, Liang R, Leung YH, et al. Philadelphia (Ph) chromosome-positive chronic myeloid leukaemia relapsing as Ph-negative leukaemia after allogeneic bone marrow transplantation. Br J Haematol 2001;114:365-8.
75. Jin Huh H, Won Huh J, Myong Seong C, Lee M, Soon Chung W. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. Am J Hematol 2003;74:218-20.